论文部分内容阅读
Sapropterin dihydrochloride于2007年12月13日获得美国FDA批准上市,为四氢生物喋呤(BH4)类药物,最初由Asubio Pharma公司研发,商品名为Kuvan。本品为口服制剂(片剂规格为100mg/片[1]),临床上用于治疗苯丙酮尿症。Sapropterin dihydrochloride的中文化学名称:(6R)-2-氨基-6-[(1
Sapropterin dihydrochloride was approved by the U.S. FDA on December 13, 2007 and is a tetrahydrobiopterin (BH4) drug originally developed by Asubio Pharma Company under the trade name Kuvan. This product is an oral preparation (tablet size is 100mg / tablet [1]), clinically used for the treatment of phenylketonuria. Chinese chemical name of Sapropterin dihydrochloride: (6R) -2-Amino-6 - [(1